CN112345318A - Compound sputum digestive juice - Google Patents
Compound sputum digestive juice Download PDFInfo
- Publication number
- CN112345318A CN112345318A CN202011050843.4A CN202011050843A CN112345318A CN 112345318 A CN112345318 A CN 112345318A CN 202011050843 A CN202011050843 A CN 202011050843A CN 112345318 A CN112345318 A CN 112345318A
- Authority
- CN
- China
- Prior art keywords
- sputum
- digestive juice
- compound
- concussion
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010036790 Productive cough Diseases 0.000 title claims abstract description 184
- 208000024794 sputum Diseases 0.000 title claims abstract description 184
- 210000003802 sputum Anatomy 0.000 title claims abstract description 176
- 230000001079 digestive effect Effects 0.000 title claims abstract description 127
- 235000011389 fruit/vegetable juice Nutrition 0.000 title claims abstract description 127
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 239000003223 protective agent Substances 0.000 claims abstract description 59
- 230000009514 concussion Effects 0.000 claims abstract description 54
- 239000002518 antifoaming agent Substances 0.000 claims abstract description 48
- 239000001888 Peptone Substances 0.000 claims abstract description 44
- 108010080698 Peptones Proteins 0.000 claims abstract description 44
- 235000019319 peptone Nutrition 0.000 claims abstract description 44
- 239000004094 surface-active agent Substances 0.000 claims abstract description 40
- 230000029087 digestion Effects 0.000 claims abstract description 29
- 230000035939 shock Effects 0.000 claims abstract description 22
- 235000018102 proteins Nutrition 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 239000002131 composite material Substances 0.000 claims description 24
- 239000005416 organic matter Substances 0.000 claims description 22
- 239000002736 nonionic surfactant Substances 0.000 claims description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 150000001720 carbohydrates Chemical group 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000011814 protection agent Substances 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 4
- 238000011081 inoculation Methods 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 description 53
- 230000001580 bacterial effect Effects 0.000 description 36
- 238000010586 diagram Methods 0.000 description 30
- 230000006399 behavior Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- 230000010355 oscillation Effects 0.000 description 22
- 239000002504 physiological saline solution Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 10
- 239000013530 defoamer Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 230000034994 death Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000000721 bacterilogical effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001012 protector Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 241000242757 Anthozoa Species 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229940066779 peptones Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000251522 Cephalochordata Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002133 sample digestion Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/286—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q involving mechanical work, e.g. chopping, disintegrating, compacting, homogenising
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a compound sputum digestive juice, and belongs to the technical field of sputum digestion. The compound sputum digestive juice comprises sputum digestive juice and a shock protective agent; the shock protective agent comprises any one or a combination of an antifoaming agent, a surfactant and peptone. When the compound sputum digestive juice is used for concussion digestion, the sputum sample can be rapidly digested, the digestion effect is guaranteed, meanwhile, microorganisms are prevented from being cracked and dead in the concussion process, and the accuracy of an inoculation result is improved.
Description
Technical Field
The invention relates to a compound sputum digestive juice, and belongs to the technical field of sputum digestion.
Background
Sputum samples, urine, secretions, feces and the like are common samples in clinic. The sputum sample is the sample with the largest sample amount in China at present and accounts for about 70% of the total amount of the sample. The sputum sample is a semisolid non-uniform sample, pathogenic bacteria are often wrapped in mucus, and the sputum sample is randomly sampled and directly tested, so that missed detection or false detection is easily caused, and the sputum sample needs to be tested after bacteriological culture. Sputum sample homogenization (commonly referred to as sputum digestion) is an important step in sputum bacteriological culture.
The sputum sample is homogenized by adding sputum digestive juice to the sputum sample and then carrying out incubation digestion. The sputum digestive juice commonly used in the prior art comprises pancreatin sputum digestive juice, alpha-chymotrypsin sputum digestive juice, N-acetyl-L-cysteine sputum digestive juice, Sputasol sputum digestive juice and the like. To ensure digestion, digestion times are usually longer (up to 1 hour) in incubation, which is not conducive to rapid inoculation. And the sample added with the sputum digestive juice is vibrated to realize rapid digestion, but the vibration digestion is easy to cause bacterial lysis and death, thereby influencing the accuracy of the detection result.
Disclosure of Invention
The invention aims to provide a compound sputum digestive juice, which can solve the problem that microorganisms are easy to crack and die when the existing sputum digestive juice is vibrated and digested.
The invention also provides application of the composite sputum digestive juice.
In order to realize the purpose, the technical scheme adopted by the composite sputum digestive juice is as follows:
a compound phlegm digestive juice comprises phlegm digestive juice and concussion protective agent; the shock protective agent comprises any one or a combination of an antifoaming agent, a surfactant and peptone.
When the compound sputum digestive juice is used for concussion digestion, the sputum sample can be rapidly digested, the digestion effect is guaranteed, meanwhile, microorganisms are prevented from being cracked and dead in the concussion process, and the accuracy of an inoculation result is improved. Particularly, when concussion digestion is carried out, the composite sputum digestive juice can ensure that streptococcus pyogenes, oral streptococcus, moraxella catarrhalis, nocardia and the like are not cracked and die.
The sputum digestive juice is a commercial product or is prepared by self according to the prior art, for example, a commercial pancreatin sputum digestive juice, alpha-chymotrypsin sputum digestive juice, N-acetyl-L-cysteine sputum digestive juice, Oxoid Sputasol sputum digestive juice or DTT-containing sputum digestive juice, and the sputum digestive juice is mixed with a concussion protective agent and then is used according to the original specification.
Preferably, the defoamer is a silicon-free defoamer. The silicon-free antifoaming agent is preferably a fermentation food grade silicon-free antifoaming agent. For example, the silicon-free defoamer is a silicon-free defoamer F1152 and/or a silicon-free defoamer DF-103.
Preferably, the surfactant is a nonionic surfactant. Further preferably, the nonionic surfactant is selected from any one or a combination of polyoxyethylene type nonionic surfactants and polyhydric alcohol type nonionic surfactants. For example, the polyoxyethylene type nonionic surfactant is polyethylene glycol. The average molecular weight of the polyethylene glycol is 2000-6000. Preferably, the polyoxyethylene nonionic surfactant is any one or a combination of polyethylene glycol 2000 and polyethylene glycol 6000. For example, the polyhydric alcohol type nonionic surfactant is a tween type nonionic surfactant. Preferably, the polyhydric alcohol type nonionic surfactant is one or two selected from tween-20 and tween-80.
Preferably, the mass of the concussion protective agent adopted for every 1L of sputum digestive juice is 0.01-41 g. For example, the concussion protective agent used per 1L of sputum digestive juice may have a mass of 0.05g, 0.1g, 0.2g, 0.3g, 0.4g, 0.5g, 0.6g, 0.7g, 0.8g, 0.9g, 1g, 2g, 3g, 4g, 5g, 6g, 7g, 8g, 9g, 10g, 11g, 12g, 13g, 14g, 15g, 16g, 17g, 18g, 19g, 20g, 21g, 22g, 23g, 24g, 25g, 26g, 27g, 28g, 29g, 30g, 31g, 32g, 33g, 34g, 35g, 36g, 37g, 38g, 39g, or 40 g.
Preferably, the shock protection agent comprises an antifoaming agent. More preferably, the amount of the antifoaming agent used is 0.01 to 1g per 1L of the sputum-digesting solution. For example, the amount of the antifoaming agent used is 0.05g, 0.1g, 0.2g, 0.3g, 0.4g, 0.5g, 0.6g, 0.7g, 0.8g, or 0.9g per 1L of the sputum-digesting solution. When the shock protective agent comprises an antifoaming agent, the shock protective agent is an antifoaming agent or a combination of at least one of a surfactant and peptone and the antifoaming agent, such as antifoaming agent + surfactant, antifoaming agent + peptone, antifoaming agent + surfactant + peptone.
Preferably, the concussion protector comprises a surfactant. More preferably, the surfactant is used in an amount of 0.1-10g per 1L of the sputum-digesting solution. For example, the surfactant is used in an amount of 0.5g, 1g, 2g, 3g, 4g, 5g, 6g, 7g, 8g, or 9g per 1L of sputum-digesting solution. When the shock protective agent comprises a surfactant, the shock protective agent is a combination of at least one of a surfactant or an antifoaming agent and peptone and the surfactant, such as surfactant + antifoaming agent, surfactant + peptone, antifoaming agent + surfactant + peptone.
Preferably, the concussion protector comprises peptone. Further preferably, the mass of peptone used per 1L of sputum-digesting solution is 1-10 g. For example, the mass of peptone used per 1L of sputum-digesting solution is 1g, 2g, 3g, 4g, 5g, 6g, 7g, 8g or 9 g. When the shock protective agent comprises peptone, the shock protective agent is a combination of at least one of peptone or antifoaming agent, and surfactant and peptone, such as peptone + antifoaming agent, peptone + surfactant peptone + antifoaming agent + surfactant. The protein is animal source peptone and/or plant source peptone. The peptone is preferably a peptone of animal origin.
Preferably, the shock protective agent further comprises a polyhydroxy organic compound. The mass of the polyhydroxy organic matter adopted by every 1L of sputum digestive juice is 1-10 g. For example, the amount of polyhydroxylated organic substances used per 1L of sputum-digesting solution is 2g, 3g, 4g, 5g, 6g, 7g, 8g or 9 g. The polyhydroxy organic matter is carbohydrate. The saccharide can be one or any combination of disaccharide and polysaccharide. Preferably, the saccharide substance is any one or combination of dextrin, trehalose and sucrose. When the shock protective agent still includes the polyhydroxy organic matter, the shock protective agent includes the combination that at least one formed in polyhydroxy organic matter and defoaming agent, surfactant active, peptone, for example, be polyhydroxy organic matter + defoaming agent, polyhydroxy organic matter + surfactant active, polyhydroxy organic matter + peptone, polyhydroxy organic matter + defoaming agent + surfactant active, polyhydroxy organic matter + defoaming agent + peptone, polyhydroxy organic matter + surfactant active + peptone or polyhydroxy organic matter + defoaming agent + surfactant active + peptone.
Preferably, the concussion protection agent further comprises a protein. The mass of the protein correspondingly adopted in each 1L of sputum digestive juice is 1-10 g. For example, the amount of protein used per 1L of sputum-digesting solution is 2g, 3g, 4g, 5g, 6g, 7g, 8g or 9 g. The protein is any one or combination of bovine serum albumin and casein. The albumin is preferably bovine serum albumin. When the concussion protector further comprises a protein, the concussion protector comprises a combination of the protein and at least one of an antifoaming agent, a surfactant and a peptone, such as protein + antifoaming agent, protein + surfactant, protein + peptone, protein + antifoaming agent + surfactant, protein + antifoaming agent + peptone, protein + surfactant + peptone or protein + antifoaming agent + surfactant + peptone. When the shock protective agent contains at least one of polyhydroxy organic matter, protein, defoaming agent, surfactant and peptone, the shock protective agent is protein + polyhydroxy organic matter + defoaming agent, protein + polyhydroxy organic matter + surfactant, protein + polyhydroxy organic matter + peptone, protein + polyhydroxy organic matter + defoaming agent + surfactant, protein + polyhydroxy organic matter + defoaming agent + peptone, protein + polyhydroxy organic matter + surfactant + peptone or protein + polyhydroxy organic matter + defoaming agent + surfactant + peptone.
By way of example, the composite sputum digestive juice of the present invention may be sputum digestive juice + defoamer, sputum digestive juice + surfactant, sputum digestive juice + peptone, or sputum digestive juice + defoamer + surfactant, sputum digestive juice + peptone + defoamer, sputum digestive juice + defoamer + surfactant + peptone. The preparation method of the compound sputum digestive juice comprises the following steps: mixing the sputum digestive juice and the concussion protective agent uniformly.
Drawings
FIG. 1 is a comparison of sputum samples before and after concussion in Experimental example 2;
FIG. 2 is a comparison of sputum samples before and after concussion in Experimental example 3;
FIG. 3 is a comparison of sputum samples before and after concussion in Experimental example 4;
FIG. 4 is a comparison of sputum samples before and after concussion in Experimental example 5;
FIG. 5 is a graph comparing the sputum sample before and after shaking in Experimental example 6.
Detailed Description
The present invention will be further described with reference to the following embodiments.
The animal-derived peptones used in the examples were bacteriological peptones purchased from master of Elytrigs, Baikholderia, Inc.
The Anthony biological sputum digestion solution used in the examples was a commercially available sputum sample digestion solution (Yuzheng Yu Shi 20190184, main component DTT) produced by Zhengzhou Antu bioengineering GmbH, and the Oxoid sputum digestion solution was a sputum digestion solution (Sputasol) product produced by Oxoid.
The silicon-free antifoaming agent F1152 and the silicon-free antifoaming agent DF-103 adopted in the examples are purchased from Shenzhen Dayang New Material Co.
Example 1
The compound sputum digestive juice of the embodiment is composed of sputum digestive juice and a concussion protective agent; the mass of the concussion protective agent adopted for every 1L of sputum digestive juice is 0.1 g; wherein the sputum digestive juice is the biological sputum sample digestive juice of the angstrom, and the concussion protective agent is a silicon-free antifoaming agent F1152. The preparation method of the composite sputum digestive juice comprises the following steps: and (3) uniformly mixing the sputum sample digestive juice and the concussion protective agent to obtain the sputum sample digestive juice.
Example 2
The compound sputum digestive juice of the embodiment is composed of sputum digestive juice and a concussion protective agent; the mass of the shock protective agent adopted for each 1L of sputum digestive juice is 1 g; wherein the sputum digestive juice is a biological sputum sample digestive juice of the angstrom, and the concussion protective agent is Tween-20. The preparation method of the composite sputum digestive juice comprises the following steps: mixing the phlegm digestive juice and the concussion protective agent uniformly to obtain the composition.
Example 3
The compound sputum digestive juice of the embodiment is composed of sputum digestive juice and a concussion protective agent; wherein the sputum digestive juice is a biological sputum sample digestive juice of the angstrom, and the concussion protective agent is Tween-20 and a silicon-free antifoaming agent F1152; each 1L of sputum digestion solution corresponds to 1g of Tween-20 and 0.1g of silicon-free antifoaming agent F1152. The preparation method of the composite sputum digestive juice comprises the following steps: mixing the phlegm digestive juice and the concussion protective agent uniformly to obtain the composition.
Examples 4 to 42
The compound sputum digestive juice of examples 4-42 is composed of sputum digestive juice and concussion protective agent, and the dosage of the sputum digestive juice, concussion protective agent and concussion protective agent specifically adopted in each example is shown in table 1.
TABLE 1 dosage of sputum digestant, concussion protectant and concussion protectant used in examples 4-42
The compound sputum digestive juice in the above examples 4 to 42 is prepared by uniformly mixing the sputum digestive juice and the concussion protective agent.
Comparative example 1
The sputum digestive juice of the comparative example is the same as that of example 1, and no concussion protective agent is added in the sputum digestive juice.
Experimental example 1
Taking 42 parts of 1ml sputum samples, and digesting the sputum samples according to the digestion methods of the sputum samples in the embodiments 1-42; in addition, 42 comparative examples which correspond to 42 embodiments in a one-to-one mode are arranged, and each comparative example is different from the corresponding embodiment only in that the adopted oscillation protective agent is omitted; 1mL of the same sputum sample as in the corresponding example was digested according to the respective ratios.
Then, 10 microliters of each digested treatment solution was respectively pipetted by a pipette and inoculated onto a corresponding culture medium (each pair of ratios is identical to the culture medium of the corresponding example), streaking was performed by using an inoculating loop, and finally, bacteriological culture was performed at 35 to 37 ℃, and then the viable count in each culture medium was counted by using a plate counting method for one or more randomly selected bacteria (each pair of ratios is identical to the bacteria selected in the corresponding example), and the results are shown in table 2.
TABLE 2 statistics of viable count of selected bacteria in culture media of each example and corresponding comparative example
As can be seen from the data in Table 2, the sputum digestive juice added with the concussion protective agent has a good protective effect on bacteria in the sputum sample.
Experimental example 2
Preparing 0.5M bacteria suspension from freshly activated Moraxella catarrhalis ATCC25238, taking 3 parts of the completely identical bacteria suspension (1 mL each), adding 1mL of physiological saline to 1 part (1 st part) of the completely identical bacteria suspension, adding 1mL of Antu biological sputum digestion solution to 1 part (2 nd part), adding 1mL of compound sputum digestion solution to 1 part (3 rd part), and then shaking for 10min at room temperature. Wherein the compound sputum digestive juice is obtained by adding and mixing a concussion protective agent into the angleonian biological sputum digestive juice, and the mass of the concussion protective agent added into each 1L of angleonian biological sputum digestive juice is 1 g; the concussion protective agent adopted is tween 80.
The morphology of each of the strains before and after the oscillation is shown in FIG. 1, wherein the 1 st behavior in the 1 st column is a schematic diagram of adding physiological saline into the 1 st bacterial suspension without oscillation, and the 2 nd to 3 rd behaviors in the 1 st column are a schematic diagram of adding physiological saline into the 1 st bacterial suspension after oscillation. The schematic diagram that the 2 nd bacterial suspension of the 1 st action in the column 2 is added into the atlas biological sputum digestive juice without oscillation, and the schematic diagram that the 2 nd bacterial suspension of the 2 nd action to the 3 rd action in the column 2 is added into the atlas biological sputum digestive juice after oscillation. The schematic diagram of the 3 rd behavior in the 3 rd row after adding the 3 rd bacterial suspension into the compound sputum digestive juice and not shaking the 1 st behavior in the 3 rd row, and the schematic diagram of the 3 rd behavior in the 3 rd row after adding the 3 rd bacterial suspension into the compound sputum digestive juice and shaking the 3 rd behavior. As can be seen from FIG. 1, the shaking itself leads to the death of the bacterial colony, and the bacterial colony after shaking by using the compound sputum digestive juice is obviously more than that of the Anthogama biological sputum digestive juice without the shake protective agent.
Experimental example 3
A0.5M bacterial suspension was prepared from freshly activated Streptococcus pyogenes ATCC19615, 3 portions of the same bacterial suspension (1 mL each) were taken, 1 portion (1 st portion) of the same bacterial suspension was added with 1mL of the complex sputum digest, 1 portion (2 nd portion) of the same bacterial suspension was added with 1mL of physiological saline, and finally 1 portion (3 rd portion) of the same sputum digest was added with 1mL of the Amphioxus sputum digest, followed by shaking at room temperature for 10 min. Wherein the compound sputum digestive juice is obtained by adding and mixing a concussion protective agent into the angleograph biological sputum digestive juice, and the mass of the concussion protective agent added into each 1L of angleograph biological sputum digestive juice is 1 g; the concussion protective agent adopted is tween 80.
The morphology of each suspension before and after oscillation is shown in fig. 2, wherein the 1 st behavior in the 1 st column is a schematic diagram of adding the 1 st suspension into the composite sputum digestive juice without oscillation, and the 2 nd to 3 rd behaviors in the 1 st column are a schematic diagram of adding the 1 st suspension into the composite sputum digestive juice after oscillation. Wherein the 2 nd behavior in the 2 nd row is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline without shaking, and the 2 nd behavior in the 2 nd row to the 3 rd behavior is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline after shaking. The schematic diagram that the 3 rd bacterial suspension of the 1 st action in the 3 rd row is added into the atlas biological sputum digestive juice without oscillation, and the schematic diagram that the 3 rd bacterial suspension of the 2 nd to 3 rd actions in the 3 rd row is added into the atlas biological sputum digestive juice after oscillation. As can be seen from FIG. 2, the shaking itself resulted in the death of the colonies, and the number of the colonies after shaking using the compound sputum digestive juice was significantly higher than that of the Anthozoa sputum digestive juice without the shake protective agent.
Experimental example 4
A0.5M bacterial suspension was prepared from freshly activated Streptococcus oralis ATCC6429, 3 identical bacterial suspensions (1 mL each) were taken from the suspension, 1 part (1 st part) of the suspension was added with 1mL of the complex sputum digest, 1 part (2 nd part) of the suspension was added with 1mL of physiological saline, and finally 1 part (3 rd part) of the suspension was added with 1mL of OXOID sputum digest, followed by shaking at room temperature for 10 min. Wherein the compound sputum digestive juice is obtained by adding the concussion protective agent into OXOID sputum digestive juice and mixing; the adopted concussion protective agent is Tween 80 and a silicon-free defoaming agent F1152, the mass of the Tween 80 added in 1L of OXOID sputum digestion solution is 1g, and the mass of the silicon-free defoaming agent F1152 added is 0.1 g.
The morphology of each strain before and after oscillation is shown in fig. 3, wherein the 1 st behavior in the 1 st column is a schematic diagram of adding the 1 st strain suspension into the composite sputum digestive juice without oscillation, and the 2 nd to 3 rd behaviors in the 1 st column are a schematic diagram of adding the 1 st strain suspension into the composite sputum digestive juice after oscillation. Wherein the 2 nd behavior in the 2 nd row is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline without shaking, and the 2 nd behavior in the 2 nd row to the 3 rd behavior is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline after shaking. The schematic diagram of the 3 rd bacterial suspension added with OXOID sputum digestive juice in the 1 st row in the 3 rd column, and the schematic diagram of the 3 rd bacterial suspension added with OXOID sputum digestive juice in the 2 nd to 3 rd rows in the 3 rd column after concussion. As can be seen from FIG. 3, the shaking itself resulted in the death of colonies, and the number of colonies after shaking with the compound sputum-containing digestion solution was significantly greater than that of OXOID sputum-containing digestion solution without the shake protectant.
Experimental example 5
Preparing 0.5 M.suspension from freshly activated stenotrophomonas maltophilia ATCC17666, taking 3 parts of the completely same bacterial suspension (1 mL each), then optionally taking 1 part (1 st part) of the suspension, adding 1mL of composite sputum digestion solution, taking 1 part (2 nd part) of the suspension, adding 1mL of physiological saline, finally adding 1mL of OXOID sputum digestion solution into 1 part (3 rd part), and then shaking for 10min in a room-temperature environment. Wherein the compound sputum digestive juice is obtained by adding the concussion protective agent into OXOID sputum digestive juice and mixing; the adopted concussion protective agent is Tween 80 and a silicon-free defoaming agent F1152, the mass of the Tween 80 added in each 1L of OXOID sputum digestion solution is 2g, and the mass of the silicon-free defoaming agent F1152 added is 0.1 g.
The morphology of each suspension before and after oscillation is shown in fig. 4, wherein the 1 st behavior in the 1 st column is a schematic diagram of adding the 1 st suspension into the composite sputum digestive juice without oscillation, and the 2 nd to 3 rd behaviors in the 1 st column are a schematic diagram of adding the 1 st suspension into the composite sputum digestive juice after oscillation. Wherein the 2 nd behavior in the 2 nd row is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline without shaking, and the 2 nd behavior in the 2 nd row to the 3 rd behavior is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline after shaking. The schematic diagram of the 3 rd bacterial suspension added with OXOID sputum digestive juice in the 1 st row in the 3 rd column, and the schematic diagram of the 3 rd bacterial suspension added with OXOID sputum digestive juice in the 2 nd to 3 rd rows in the 3 rd column after concussion. As can be seen from FIG. 4, the shaking itself resulted in the death of colonies, and the number of colonies after shaking with the compound sputum-containing digestion solution was significantly greater than that of OXOID sputum-containing digestion solution without the shake protectant.
Experimental example 6
Preparing 0.5 McLeod bacterial suspension by using a fresh activated nocardia asteroides clinical strain, taking 3 parts of completely same bacterial suspension (each part is 1mL), then optionally taking 1 part (1 st part) of the bacterial suspension, adding 1mL of composite sputum digestive juice, taking 1 part (2 nd part) of the bacterial suspension, adding 1mL of normal saline, finally adding 1mL of Ampere biological sputum digestive juice into 1 part (3 rd part), and then shaking for 10min in a room-temperature environment. Wherein the compound sputum digestive juice is obtained by adding a shock protective agent into the angstrom biological sputum digestive juice and mixing, and the mass of the shock protective agent adopted by every 1L of angstrom biological sputum digestive juice is 1 g; the concussion protective agent adopted is tween 80.
The morphology of each strain before and after oscillation is shown in fig. 5, wherein the 1 st behavior in the 1 st column is a schematic diagram of adding the 1 st strain suspension into the composite sputum digestive juice without oscillation, and the 2 nd to 3 rd behaviors in the 1 st column are a schematic diagram of adding the 1 st strain suspension into the composite sputum digestive juice after oscillation. Wherein the 2 nd behavior in the 2 nd row is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline without shaking, and the 2 nd behavior in the 2 nd row to the 3 rd behavior is a schematic diagram of adding the 2 nd bacterial suspension into the physiological saline after shaking. The schematic diagram that the 3 rd bacterial suspension of the 1 st action in the 3 rd row is added into the atlas biological sputum digestive juice without oscillation, and the schematic diagram that the 3 rd bacterial suspension of the 2 nd to 3 rd actions in the 3 rd row is added into the atlas biological sputum digestive juice after oscillation. As can be seen from FIG. 5, the shaking itself resulted in the death of the colonies, and the number of the colonies after shaking using the compound sputum digestive juice was significantly higher than that of the Anthozoa sputum digestive juice without the shake protective agent.
Claims (16)
1. A compound sputum digestive juice is characterized in that: comprises sputum digestive juice and concussion protective agent; the shock protective agent comprises any one or a combination of an antifoaming agent, a surfactant and peptone.
2. The compound sputum digestive juice according to claim 1, characterized in that: the defoaming agent is a silicon-free defoaming agent.
3. The compound sputum digestive juice according to claim 1, characterized in that: the surfactant is a nonionic surfactant.
4. The compound sputum digestive juice according to claim 3, characterized in that: the nonionic surfactant is selected from any one or combination of polyoxyethylene type nonionic surfactants and polyhydric alcohol type nonionic surfactants.
5. The compound sputum digestive juice according to claim 4, characterized in that: the polyoxyethylene nonionic surfactant is any one or combination of polyethylene glycol 2000 and polyethylene glycol 6000.
6. The compound sputum digestive juice according to claim 4, characterized in that: the polyhydric alcohol type nonionic surfactant is selected from one or two of tween-20 and tween-80.
7. The compound sputum digestive juice according to claim 1, characterized in that: the mass of the concussion protective agent adopted for every 1L of sputum digestive juice is 0.01-41 g.
8. The composite sputum digest of claim 1 or 2, wherein: the shock protective agent comprises a defoaming agent; the mass of the antifoaming agent adopted for every 1L of sputum digestive juice is 0.01-1 g.
9. The composite sputum digest of claim 1 or 3, wherein: the shock protection agent comprises a surfactant; the surfactant is 0.1-10g per 1L of sputum digestive juice.
10. The composite sputum digest of claim 1 or 4, wherein: the concussion protective agent comprises peptone; the mass of peptone used per 1L of sputum digestion solution is 1-10 g.
11. The compound sputum digestive juice according to claim 1, characterized in that: the shock protective agent also comprises a polyhydroxy organic matter.
12. The compound sputum digestive juice according to claim 11, wherein: the polyhydroxy organic matter is carbohydrate; the saccharide is any one or combination of dextrin, trehalose and sucrose.
13. The composite sputum digest of claim 11 or 12, wherein: the mass of the polyhydroxy organic matter adopted by every 1L of sputum digestive juice is 1-10 g.
14. The composite sputum digest of claim 1 or 11 or 12, wherein: the concussion protection agent also includes a protein.
15. The composite sputum digest of claim 14, wherein: the protein is any one or combination of bovine serum albumin and casein.
16. The composite sputum digest of claim 14, wherein: the mass of the protein correspondingly adopted in each 1L of sputum digestive juice is 1-10 g.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011050843.4A CN112345318B (en) | 2020-09-29 | 2020-09-29 | Compound phlegm digestive juice |
| PCT/CN2021/120814 WO2022068746A1 (en) | 2020-09-29 | 2021-09-27 | Composite sputum digestion liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011050843.4A CN112345318B (en) | 2020-09-29 | 2020-09-29 | Compound phlegm digestive juice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112345318A true CN112345318A (en) | 2021-02-09 |
| CN112345318B CN112345318B (en) | 2024-05-17 |
Family
ID=74361352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011050843.4A Active CN112345318B (en) | 2020-09-29 | 2020-09-29 | Compound phlegm digestive juice |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112345318B (en) |
| WO (1) | WO2022068746A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022068746A1 (en) * | 2020-09-29 | 2022-04-07 | 郑州安图生物工程股份有限公司 | Composite sputum digestion liquid |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4053363A (en) * | 1976-06-28 | 1977-10-11 | J. K. And Susie L. Wadley Research Institute And Blood Bank | Sputum analysis method |
| EP0571203A1 (en) * | 1992-05-22 | 1993-11-24 | Becton, Dickinson and Company | Transporting medium for microorganism specimen containing white blood cell lytic agents |
| CN104232621A (en) * | 2014-09-23 | 2014-12-24 | 宁波有成生物医药科技有限公司 | Kit for extracting nucleic acid from sputum and extraction method |
| CN104254597A (en) * | 2012-02-29 | 2014-12-31 | Bd公司 | Formulations and process for isolating viable microorganism from positive blood cultures |
| CN104531659A (en) * | 2014-12-16 | 2015-04-22 | 四川新健康成生物股份有限公司 | Trypsin digestive juice, preparation method and ready-to-use phlegm digesting device |
| CN105506085A (en) * | 2015-12-28 | 2016-04-20 | 北京澳利文生物科技有限公司 | Treating method for viscous fluid specimen |
| CN105524988A (en) * | 2015-12-31 | 2016-04-27 | 上海星耀医学科技发展有限公司 | Kit for rapid detection of Mycobacterium tuberculosis in sputum |
| CN107667168A (en) * | 2015-05-27 | 2018-02-06 | 凯杰有限公司 | Composition and method for disrupting tissue material |
| WO2019222862A1 (en) * | 2018-05-25 | 2019-11-28 | Qvella Corporation | Methods and compositions for the selective lysis of blood cells and separation of microbial cells |
| CN111238893A (en) * | 2020-01-19 | 2020-06-05 | 湖北泰康医疗设备有限公司 | Method for extracting humoral cells for detecting lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101158647A (en) * | 2007-11-13 | 2008-04-09 | 天津市疾病预防控制中心 | Legionella pneumophila biochemical reaction identification method |
| CN103146799A (en) * | 2013-03-28 | 2013-06-12 | 中国人民解放军第三军医大学 | Kit for microbial detection |
| CN104561230B (en) * | 2015-01-22 | 2015-09-02 | 四川金域医学检验中心有限公司 | A kind of medical science detects the preparation of sputum sample homogeneity method and reagent |
| WO2017088169A1 (en) * | 2015-11-27 | 2017-06-01 | Coyote Bioscience Co., Ltd. | Methods and systems for nucleic acid amplification |
| CN206531717U (en) * | 2017-02-23 | 2017-09-29 | 郑州安图生物工程股份有限公司 | The sample adding system of automatic addition phlegm digestive juice |
| CN112345318B (en) * | 2020-09-29 | 2024-05-17 | 郑州安图生物工程股份有限公司 | Compound phlegm digestive juice |
-
2020
- 2020-09-29 CN CN202011050843.4A patent/CN112345318B/en active Active
-
2021
- 2021-09-27 WO PCT/CN2021/120814 patent/WO2022068746A1/en active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4053363A (en) * | 1976-06-28 | 1977-10-11 | J. K. And Susie L. Wadley Research Institute And Blood Bank | Sputum analysis method |
| EP0571203A1 (en) * | 1992-05-22 | 1993-11-24 | Becton, Dickinson and Company | Transporting medium for microorganism specimen containing white blood cell lytic agents |
| CN104254597A (en) * | 2012-02-29 | 2014-12-31 | Bd公司 | Formulations and process for isolating viable microorganism from positive blood cultures |
| CN104232621A (en) * | 2014-09-23 | 2014-12-24 | 宁波有成生物医药科技有限公司 | Kit for extracting nucleic acid from sputum and extraction method |
| CN104531659A (en) * | 2014-12-16 | 2015-04-22 | 四川新健康成生物股份有限公司 | Trypsin digestive juice, preparation method and ready-to-use phlegm digesting device |
| CN107667168A (en) * | 2015-05-27 | 2018-02-06 | 凯杰有限公司 | Composition and method for disrupting tissue material |
| CN105506085A (en) * | 2015-12-28 | 2016-04-20 | 北京澳利文生物科技有限公司 | Treating method for viscous fluid specimen |
| CN105524988A (en) * | 2015-12-31 | 2016-04-27 | 上海星耀医学科技发展有限公司 | Kit for rapid detection of Mycobacterium tuberculosis in sputum |
| WO2019222862A1 (en) * | 2018-05-25 | 2019-11-28 | Qvella Corporation | Methods and compositions for the selective lysis of blood cells and separation of microbial cells |
| CN111238893A (en) * | 2020-01-19 | 2020-06-05 | 湖北泰康医疗设备有限公司 | Method for extracting humoral cells for detecting lung cancer |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022068746A1 (en) * | 2020-09-29 | 2022-04-07 | 郑州安图生物工程股份有限公司 | Composite sputum digestion liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022068746A1 (en) | 2022-04-07 |
| CN112345318B (en) | 2024-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vidaver et al. | Bacteriophage φ6: a lipid-containing virus of Pseudomonas phaseolicola | |
| Doyle et al. | Selective-enrichment procedure for isolation of Listeria monocytogenes from fecal and biologic specimens | |
| Chesneau et al. | Staphylococcus pasteuri sp. nov., isolated from human, animal, and food specimens | |
| Schoenborn et al. | Liquid serial dilution is inferior to solid media for isolation of cultures representative of the phylum-level diversity of soil bacteria | |
| Crespo et al. | Evaluation of different preservation and storage methods for Malassezia spp | |
| WO2016122128A1 (en) | Novel lactobacillus plantarum bacteriophage lac-plp-1 and use thereof for inhibiting lactobacillus plantarum proliferation | |
| CN112345318A (en) | Compound sputum digestive juice | |
| WO2016122127A1 (en) | Novel lactobacillus brevis bacteriophage lac-brp-1 and use thereof for inhibiting lactobacillus brevis proliferation | |
| Oram et al. | The adsorption of phage to group N streptococci. The specificity of adsorption and the location of phage receptor substances in cell-wall and plasma-membrane fractions | |
| CN112345319B (en) | Digestion method of sputum sample | |
| CN113652371A (en) | Ultrahigh-temperature kitchen waste treatment microbial inoculum and preparation method thereof | |
| EP2163239A1 (en) | Products containing bioparticles, method for their manufacture | |
| Woodruff et al. | A bacterial virus for Actinomyces griseus | |
| Carriere et al. | Nocardia thyroiditis: unusual location of infection | |
| Gramoli et al. | Characterization and identification of coagulase-negative, heat-stable deoxyribonuclease-positive staphylococci | |
| Joklik et al. | Reactivation of poxviruses by a non-genetic mechanism | |
| Holmgaard et al. | Bacteremia and urogenital infection with Actinomyces urogenitalis following prolonged urinary retention | |
| Dhakal et al. | Saccharopolyspora species: laboratory maintenance and enhanced production of secondary metabolites | |
| Heald et al. | A method for direct viable counts of the facultatively anaerobic microflora in the rumen of a sheep maintained on a hay diet | |
| CN105950571A (en) | Proliferation method of siniperca chuatsi infectious spleen and kidney necrosis virus (ISKNV) based on epithelioma papulosum cyprinid (EPC) | |
| Wen et al. | Effective treatment of a broad-host-range lytic phage SapYZU15 in eliminating Staphylococcus aureus from subcutaneous infection | |
| MacPherson et al. | L forms of bacteria as contaminants in tissue culture | |
| Burbick et al. | An update on novel taxa and revised taxonomic status of bacteria isolated from non-domestic animals described in 2022 | |
| Atwa et al. | Lactic acid bacteria: economic propagation, chitinases activity, and enhancing viability by gel encapsulation | |
| Border et al. | Tube culture method for viable counts of Campylobacter fetus (Vibrio fetus) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |